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Abstract: Rabeprazole is a proton pump inhibitor. Pharmacodynamic data show rabeprazole can 
achieve optimal acid suppression since the ﬁ  rst administration and can maintain this advantage 
in the following days of therapy. Moreover, rabeprazole has the highest pKa (~ 5.0, the pH 
at which a drug becomes 50% protonated), and hence the molecule can be activated at higher 
pH levels much faster than other PPIs. Due to its peculiar catabolic pathway, ie, a prevalent 
metabolism through a non-enzymatic pathway, rabeprazole is less susceptible to the inﬂ  uence 
of genetic polymorphisms for CYP2C19, resulting in minor inﬂ  uences on its pharmacokinetics 
and pharmacodynamics. In terms of clinical efﬁ  cacy, rabeprazole 20 mg uid or 10 mg bid pro-
duced healing rates at 8 weeks similar to those obtained with omeprazole 20 mg uid in erosive 
esophagitis patients, and in NERD patients doses of 10 or 20 mg are equivalent and both are 
better than placebo at 2 and 4 weeks. To prevent symptomatic relapse, on-demand strategy 
with rabeprazole 10 mg daily appears to be ideal, due to its rapidity of onset; results on NERD 
patients have documented its superiority over placebo. Continuous treatment, however, up to 
5 years, seems to achieve better results than on-demand therapy, particularly in patients with 
esophagitis. It is debated whether in the latter halved doses (10 mg) are really equivalent to 
full dose (20 mg). Rabeprazole has been used with success in the treatment of some atypical 
GERD manifestations, such as dysphagia associated with GERD, GERD-related asthma and 
chest-pain, and in the therapy of Barrett’s esophagus. Finally, rabeprazole achieves similar 
Helicobacter pylori eradication rates compared with omeprazole and lansoprazole when co-
administrated with low or high doses of antibiotics (amoxicillin and clarithromycin). In addition, 
low doses of rabeprazole (10 mg/bid) may be effective in eradicating the pathogen
Keywords: rabeprazole, acid-related disorders, gastro-esophageal reﬂ  ux disease, Helicobacter 
pylori infection, pharmacodynamics, pharmacokinetics, therapeutic use
Introduction
Rabeprazole is a proton pump inhibitor (PPI) and as such covalently binds with and 
inactivates the gastric parietal cell proton pump (H+/K+-ATPase). This inhibits in turn 
gastric acid production and raises gastric pH. Proton pump inhibitors are indicated 
in the management of acid-related disorders such as gastroesophageal reﬂ  ux disease 
(GERD) and peptic ulcer disease, in association with Helicobacter pylori eradication 
therapy when needed.
Rabeprazole has been previously reviewed (Carswell and Goa 2001) and aim of the 
current review is to provide an update on the pharmacology and clinical proﬁ  le of oral ra-
beprazole and its use in acid-related disorders, with particular focus on its role in GERD 
maintenance therapy, its use in Barrett’s esophagus, and its cost-effectiveness.
Pharmacology
Pharmacodynamics
The most effective way to increase the pH in the stomach, and hence to reach a thera-
peutic level for GERD, is the blockage of the proton pump enzymes in the parietal cells. Therapeutics and Clinical Risk Management 2007:3(3) 364
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All PPIs, being substituted benzimidazoles, share the same 
antisecretory mechanism: to be activated, they concentrate 
in the secretory canaliculus of the parietal cell thanks to the 
acid milieu of the environment. The protonated molecules 
undergo a conversion to an active sulfenamide compound 
(the rate-limiting step) and, in this state, form covalent 
inhibiting disulﬁ  de bonds with surface-exposed cysteines 
of the active parietal cell H+/K+-ATPase. 
However, the ﬁ  ve available PPIs differ in terms of acid 
stability as the modiﬁ  ed functional substituents on the two-
ring structures give rabeprazole the highest pKa (~ 5.0, the 
pH at which a drug becomes 50% protonated), and hence 
the molecule can be activated at higher pH levels much 
faster than other PPIs: at pH 1.2 (the pH level of the cana-
licular space after meals) rabeprazole took 1.3 minutes to be 
half-activated in vitro, compared with 2.0, 2.8, and 4.6 min 
respectively for lansoprazole, omeprazole, and pantoprazole. 
At pH 5.1 (the pH during fasting), the activation half-life was 
again the shortest one for rabeprazole 7.2, 90, 84, and 282 
min, respectively (Kromer et al 1998).
In an isolated hog vesicle model, rabeprazole conﬁ  rmed 
its potent and fast onset of action: within 5 min of rabeprazole 
exposure the proton pump was near-maximally inhibited. The 
same target was reached after 30 min for lansoprazole and 
omeprazole; but pantoprazole could only inhibit the 50% of 
the pump by the end of the 50 minute test (Besancon et al 
1997).
Therefore, rabeprazole sodium produces a dose-related 
sustained inhibition of both basal and peptone meal-stimu-
lated gastric acid secretion (Lew et al 1998; Ohning et al 
2003).
It is widely recognized that the antisecretory activity of 
PPIs is predictive of their efﬁ  cacy in acid-related disorders. 
It has been shown that duodenal ulcer healing correlates with 
an intragastric pH >3 holding time of 18–20 hours, while 
erosive GERD healing with about a round-the-clock pH >4 
holding time (Burget et al 1990; Bell et al 1992).
Recent work has conﬁ  rmed the in vivo past evidence 
that rabeprazole can achieve optimal acid suppression since 
the ﬁ  rst administration and can maintain this advantage in 
the following days of therapy, resulting in a higher median 
24-hour intragastric pH and longer times with pH >3 and >4 
compared with omeprazole (Williams et al 1998).
In 2003 Pantoﬂ  ickova et al (2003) concluded that the 
higher pKa of rabeprazole might explain its major antisecre-
tory effect of the former during the ﬁ  rst 24 hours post-dose 
compared with the other PPI formulations tested. In a mul-
tiple crossover, comparative trial in 18 H. pylori-negative 
adults, rabeprazole 20 mg could reach a median 24-hour 
gastric pH of 3.4, compared with 2.9 for lansoprazole 30 mg, 
2.2 for pantoprazole 40 mg, 1.9 for omeprazole 20 mg, 1.8 
for omeprazole 20 mg MUPS (multiple unit pellet system), 
and 1.3 for placebo (p < 0.05 vs all other PPIs and placebo). 
In addition, rabeprazole maintained pH >4 for more time 
(8 hour) than the other agents (respectively 7.4, 4.9, 2.9, 3.0, 
and 0.9 hours, p  0.04 for rabeprazole vs the others).
A full article (Warrington et al in 2002) presented the 
results of a study where rabeprazole was compared with 
esomeprazole on a mg-per-mg basis: in this randomized, 
two-way crossover study, 24 healthy volunteers received 
treatment for a total of 5 days separated by a 14-day washout 
period. On day 1 the mean 24-hour intragastric pH AUC and 
mean percentage 24-hour pH >3 and >4 holding times were 
statistically greater for rabeprazole 20 mg than for esome-
prazole 20 mg. However, on day 5 the signiﬁ  cant superiority 
was registered for only intragastric pH AUC (p < 0.05).
Tolman et al (2006) have recently observed that lanso-
prazole 15 and 30 mg has a greater acid-suppression activity 
than, respectively, rabeprazole 10 and 20 mg during hours 
0–5 on days 1 and 5, whereas rabeprazole is equivalent 
or more effective during hours 11–24 on both days. In an 
open-label, randomized, crossover trial 72 healthy volun-
teers received each of the four treatments for 5 days with 
2-week washout periods and underwent continuous 24-hour 
intragastric pH-metry on baseline, 1 and 5 days. Mean per-
centage time for pH >4 and mean 24-hour pH were overall 
comparable between the two PPIs on both days 1 and 5, 
except for rabeprazole 10 mg which was statistically superior 
to lansoprazole 15 mg.
A reduced dose of rabeprazole (10 mg od) exhibited bet-
ter antisecretory activity than either omeprazole 20 mg od or 
lansoprazole 30 mg od in a study that analyzed the percentage 
of time pH 3 on each of the ﬁ  rst three days of therapy in 
8 H. pylori-negative CYP2C19 extensive metabolizers. On 
days 1, 2, and 3 the ratios were 13.6%, 35.3%, and 62.8% for 
rabeprazole 10 mg; 7.4%, 13.6%, and 26.6% for lansoprazole 
30 mg; and 6.1%, 11.4%, and 16.4% for omeprazole 20 mg 
(Saitoh et al 2002).
Again rabeprazole 10 mg provided a faster acid inhibi-
tion compared with omeprazole 10 mg in a randomized, 
double-blind, placebo-controlled, three-way crossover 
study on 27 volunteers. By the end of the 7-day treatment, 
median gastric pH was signiﬁ  cantly higher with rabeprazole 
than with omeprazole (3.7 vs 2.2, p = 0.0016) and the time 
with pH above 4 was more than doubled (10.5 vs 4.6 hours, 
p = 0.0008) (Bruley Des Varannes et al 2004).Therapeutics and Clinical Risk Management 2007:3(3) 365
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A number of researchers during recent years have 
investigated the occurrence of nocturnal gastric acid break-
through (NAB), which has been deﬁ  ned as the occurrence of 
intragastric pH dropping to below 4 for at least 1 hour during 
the 12 hours of night sleeping period, in GERD patients with 
nocturnal reﬂ  ux symptoms and have questioned whether this 
phenomenon is due to a failing efﬁ  cacy of PPIs over the 24 
hours. In 2003 Pehlivanov et al (2003) demonstrated that 
rabeprazole 20 mg, administered in the morning or in the 
evening, signiﬁ  cantly shortened the mean NAB duration 
versus the baseline recording (4.1 for rabeprazole a.m. and 
3.4 for rabeprazole p.m. vs 7.8 for baseline, p < 0.05).
Rabeprazole has also shown (Luo et al 2003) to be more 
effective than ﬁ  rst-generation PPIs in reducing the dura-
tion of NAB and, hence, increasing the nocturnal alkaline 
amplitude (NAKA), which has been deﬁ  ned as the occur-
rence of an abrupt increase in intragastric pH to above 4–6 
after sleeping, mostly in the early morning. Forty patients 
with active peptic ulcer were randomly assigned to receive 
a single oral dose of rabeprazole 10 mg, omeprazole 20 mg, 
or pantoprazole 40 mg; the intragastric pH was monitored 
1 hour before and 24 hours after the dose was given. In the 
rabeprazole group, the pH of NAB was statistically greater 
than the one in the others (1.84 vs 1.15 and 1.10 for respec-
tively rabeprazole vs omeprazole and pantoprazole, p < 0.01). 
Rabeprazole also gave a longer time of NAKA (4.65 hours) 
than omeprazole (3.22 hours) and pantoprazole (3.15 hours), 
both p < 0.05 (Luo et al 2003). It must be acknowledged 
that in Luo’s study the H. pylori status was not controlled, 
and this factor is known to inﬂ  uence the duration of NAB, 
as for example shown by the increase of NAB following H. 
pylori eradication (van Herwaarden et al 2000). It is possible 
that the newest PPIs, such as esomeprazole and the not yet 
marketed tenatoprazole, might be even better for control of 
NAB (Hunt et al 2005), although direct comparison with 
rabeprazole does not exist. 
An important aspect that may inﬂ  uence the pharmacody-
namics of PPIs is the CYP2C19 genotype status of patients. 
CYP2C19 is an isoenzyme of the cytochrome P450 involved 
in the catabolism of PPIs. As rabeprazole is less dependent 
on the polymorphism of this isoenzyme (see Pharmacoki-
netics section), its antisecretory activity is more predictable 
than that of the other PPIs, which are mainly catabolized 
through this isoenzyme. Adachi et al (2000) came to this 
conclusion when they investigated the intragastric pH in 20 
H. pylori-negative volunteers during a 7-day dosing regimen 
with rabeprazole 20 mg od or lansoprazole 30 mg od. In the 
rabeprazole group, the median day-time and night-time pH 
was not inﬂ  uenced by CYP2C19 genotype; on the other hand, 
the median pH in poor metabolizers during lansoprazole 
administration was higher than in homozygous extensive 
metabolizers and heterozygous extensive metabolizers. The 
percentage of time with pH < 4.0 had a similar outcome to 
that of median pH.
Another aspect to take into consideration is the gastric 
pH proﬁ  le, which has a regional variability in the stomach. It 
seems that this regional variability of pH proﬁ  le, in particular 
the highly acid “pocket” observed close to the cardias, may 
be involved in the occurrence of postprandial heartburn in 
GERD patients. In 2001 Fletcher et al (2001) reported the 
presence of this acid pocket, after the meal, just below the 
gastro-esophageal junction. By using a dual pH-metry of 
the stomach, and a pull-through technique, they were able 
to show a pocket of acid at the gastroesophageal junction 
that extended from the cardias across the squamocolumnar 
junction 1.8 cm into the distal esophagus and escaped the 
buffering effect of meals, remaining highly acidic (median 
pH 1.6) compared with the body of the stomach (pH 4.7; 
p < 0.001). Fletcher et al hypothesized that the acid pocket is 
likely to contribute to the high prevalence of disease at this 
site. In a recent article, rabeprazole 20 mg, administered for 8 
days in normal subjects, decreased the length, the magnitude, 
and the number of postprandial acid pockets. On day 1 and 
8 the acid pockets were 62 and 50 in the placebo group, but 
30 and 27 in the rabeprazole one (Vo et al 2005).
Considering the above data, it should be questioned 
whether for the purpose of acute therapy in GERD patients a 
reduced or a standard dose of PPI is more suitable to achieve 
optimal acid suppression (ie, an intragastric pH above 4 lasting 
for 20–22 hours a day), which is considered necessary to pro-
mote esophageal mucosal healing within 8 weeks. Shimatani 
et al investigated the acid-suppressive effects of rabeprazole, 
omeprazole and lansoprazole at reduced and standard doses. 
These authors performed a prospective, randomized, open-
label, 8-way crossover study in 9 healthy H. pylori-negative 
CYP2C19 homozygous extensive metabolizers, each of one 
took either 10 or 20 mg rabeprazole; 10, 20, or 40 omeprazole; 
15 or 30 mg lansoprazole; and placebo, all regimens once 
daily for 7 consecutive days with a washout period of at least 
2 weeks. Compared with baseline data (7%), the median values 
of the 24-hour percentage of time with pH >4 signiﬁ  cantly 
increased, but none of the 7 regimens used was able to reach 
the ideal threshold. The percentages of this threshold were: 
51% for rabeprazole 10 mg, 59% for rabeprazole 20 mg, 26% 
for omeprazole 10 mg, 48% for omeprazole 20 mg, 62% for 
omeprazole 40 mg, 34% for lansoprazole 15 mg, and 56% for Therapeutics and Clinical Risk Management 2007:3(3) 366
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lansoprazole 30 mg. NAB was observed under all regimens, 
even if rabeprazole 10 and 20 mg kept intragastric pH >4 for 
a longer time than the respective doses of the other two PPIs 
(Shimatani et al 2006).
Finally, besides its antisecretory effect, rabeprazole 20 
mg has been demonstrated to signiﬁ  cantly enhance gastric 
mucin and mucus content, both in basal and pentagastrin-
stimulated conditions (mucin content was: 0.82 and 0.96, 
respectively with rabeprazole vs 0.58 and 0.36 mg/mL, 
respectively with placebo, p < 0.05) (mucus content was 
3.31 and 3.36 with rabeprazole vs 2.28 and 1.5 mg/mL 
with placebo, p < 0.05) as well as the viscosity of gastric 
juice (24.4 and 28.47 with rabeprazole vs 19.37 and 19.20 
with placebo, p < 0.05). Similar data were observed during 
concomitant administration of rabeprazole and naproxene, 
as a result of a direct stimulatory action of rabeprazole on 
gastric mucous cells. In fact, co-administration of rabeprazole 
20 mg prevented the naproxen-induced decline of gastric 
mucin and mucus secretion in 21 asymptomatic H. pylori-
negative volunteers: during basal and pentagastrin-stimulated 
conditions, rabeprazole augmented the mucus production 
by 47% (p = 0.003) and 22%, and the mucin output by 40% 
(p = 0.05) and 67% (p = 0.003) respectively. This unique 
pharmacological property may exert a clinical beneﬁ  t in 
protecting the upper alimentary tract mucosa (Skoczylas 
et al 2003; Jaworski et al 2005).
Pharmacokinetics
Rabeprazole is marketed as an enterically coated formulation, 
due to the instability of all PPIs in acid environment. After 
oral ingestion it is relatively rapidly absorbed as maximal 
plasma concentration (Cmax) is reached between 2.8 and 5.1 
postdose (Swan et al, 1999).
The pharmacokinetics of the molecule has been shown 
to be linear in the range 10–80 mg with an overall bioavail-
ability of 52%, seen with rabeprazole 20 mg. Although Cmax 
and area under the curve (AUC) of the plasma concentration 
are proportional to the dose ingested, time to reach Cmax and 
half-life are dose-independent. This behavior conﬁ  rms that 
rabeprazole does not have a saturable ﬁ  rst-pass metabolism 
and it can be absorbed in high doses (Swan et al 1999).
Neither antacids nor food inﬂ  uence the bioavailability 
of the molecule, even if food intake delayed the absorption 
of rabeprazole 20 mg of about 1.7 h and reduced the appar-
ent elimination half-life due to a probable delayed gastric 
emptying (Swan et al 1999).
Preclinical studies have demonstrated that rabeprazole’s 
volume of distribution is 0.34 L/kg in a variety of tissues, 
including the gastric mucosa, stomach, kidney, bladder, 
liver, intestine, and thyroid. In healthy volunteers, it was 
demonstrated to be bound to plasma proteins 94.8%–97.5% 
(Swan et al 1999).
No significant accumulation occurs during repeated 
administration, as the elimination half-life is about 1 h after 
single and 1.5 h after multiple administrations. A 20 mg 
dose of rabeprazole is excreted approximately 90% in the 
urine (thioether carboxylic, glucoronide, and mercapturic 
metabolites) and 10% in the faeces (Swan et al 1999; Fuhr 
and Jetter 2002; Thjodleifsson 2004). 
In terms of its elimination, rabeprazole is unique. 
Whereas other PPIs such as omeprazole, lansoprazole, 
esomeprazole, and pantoprazole are metabolized mainly 
by CYP2C19 in the liver,  rabeprazole is metabolized 
mainly through a non-enzymatic pathway to rabeprazole-
thioether and, to a much lesser extent, by the citochrome 
P450 isoenzymes CYP2C19 (demethylated rabeprazole) 
and CYP3A4 (rabeprazole-sulfone). It is known that there 
are genetically determined differences in the activity of 
this enzyme. The genotypes of CYP2C19 are classiﬁ  ed 
into the three groups, rapid extensive metabolizer (RM), 
intermediate metabolizer (IM), and poor metabolizer (PM). 
The pharmacokinetics and pharmacodynamics of PPIs de-
pend on CYP2C19 genotype status. Plasma PPI levels and 
intragastric pHs during PPI treatment in the RM group are 
lowest, those in the IM group come next, and those in the 
PM group are highest of the three groups. These CYP2C19 
genotype-dependent differences in pharmacokinetics and 
pharmacodynamics of PPIs inﬂ  uence the cure rates for the 
gastro-esophageal reﬂ  ux disease and H. pylori infection by 
PPI-based therapies. For the better PPI-based treatment, 
doses and dosing schemes of PPIs should be optimized 
based on CYP2C19 genotype status (Furuta 2005). The 
peculiar catabolic pathway implies that rabeprazole is less 
susceptible to the inﬂ  uence of genetic polymorphisms for 
CYP2C19, resulting in minor inﬂ  uences on its pharmaco-
kinetics and pharmacodynamics.
The impact of CYP2C19 polymorphism on pharmaco-
kinetics of rabeprazole, omeprazole, and lansoprazole was 
assessed in 18 Japanese subjects (6 homozygous metaboliz-
ers, 6 heterozygous metabolizers, and 6 poor metabolizers). 
AUC, Cmax, and elimination half-life were not affected by 
CYP2C19 genotype for rabeprazole; however, AUC and 
Cmax were increased in poor metabolizers for lansoprazole 
and omeprazole (Sakai et al 2001). This predictivity of ra-
beprazole has the potential to reduce interpatient variability 
in both pharmacological and clinical effects.Therapeutics and Clinical Risk Management 2007:3(3) 367
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Patient genetic characteristics increased the intragastric pH 
after single and repeated doses in heterozygous extensive and 
poor metabolizers versus homozygous extensive metabolizers 
who took omeprazole 20 mg for 8 days. In the rabeprazole 
group the pH proﬁ  le was almost consistent in the three genetic 
subgroups (Shirai et al 2001). A similar outcome was observed 
in patients with acid-related disease (Horn 2004).
As a result of CYP2C19 polymorphism, most Caucasians 
(60%–70% homozygous extensive metabolizers, 28%–36% 
heterozygous extensive metabolizers, and 2.7%–6.1% 
homozygous poor metabolizers) can rapidly metabolize 
PPIs such as omeprazole, esomeprazole, lansoprazole, and 
pantoprazole and show a diminished acid inhibitory activity 
of these PPIs among extensive metabolizers (Furuta 2005). 
This phenomenon might be masked by the observation that 
both omeprazole and esomeprazole inhibit the activity of 
CYP2C19 through their sulfone metabolite and, hence, 
actually autoinhibit their own metabolism, resulting in a 
non-linear increase in blood levels of these PPIs following 
repeat dosing. With omeprazole 20 mg, AUC increased by 
173% and with esomeprazole by 190%–265% for the 20 and 
40 mg doses respectively (McColl and Kennerley 2002).
The prevalent non-enzymatic metabolic pathway of 
rabeprazole is also the reason for the absence of drug–drug 
interactions between this PPI and other drugs, which are 
metabolized by the isoenzymes of the cytochrome P450. 
Co-administration of rabeprazole did not affect the pharma-
cokinetics of theophylline, diazepam, warfarin, and phenytoin 
(Thjodleifsson and Cockburn 1999). The expected interference 
with the pH-dependent absorption of digoxin and ketoconazole 
is common to all PPIs (Ishizaki and Horai 1999). 
The aim of a recent Italian study was to evaluate the 
interactions of rabeprazole and two antibiotics, used in a 
1-week eradication therapy, with hepatic metabolism in a 
clinical setting. Ten patients received an eradication regimen 
based on rabeprazole 20 mg/bid, clarithromycin 500 mg/bid, 
and metronidazole 500 mg/bid; in addition to this, they 
performed a 13C-aminopyrine breath test at baseline (t0), at 
the end of therapy (t8) and after 1 month of follow-up (t38). 
The percentage of the administered dose of 13C recovered 
per hour (13C-ABT dose/hour) and the cumulative percent-
age of the administered of 13C recovered over time were 
quite similar at the three time points (13C-ABT dose/hour: 
14.0 ± 5.4, 13.5 ± 4.0, and 16.1 ± 5.6 respectively for t0, t8 
and t38; 13C-ABT cumulative dose: 2.4 ± 1.1, 2.4 ± 0.8, and 
2.6 ± 1.0 respectively for t0, t8, and t38), conﬁ  rming the ab-
sence of interactions of concomitant drugs at hepatic level 
(Giannini et al 2005).
Although the pharmacokinetic proﬁ  le of rabeprazole 
is altered in the elderly (Cmax increased by 60% and AUC 
doubled after a 7-day treatment with rabeprazole 20 mg) 
and in patients with mild to moderate compensated hepatic 
dysfunction (Cmax increased by 50% and AUC doubled after 
a single dose of rabeprazole 20 mg), but not in patients with 
renal failure (after a dose of rabeprazole 20 mg on the day 
after hemodialysis and a second dose after a 2-week washout 
period during dialysis), no dosage adjustment is required 
in special populations, considering the evidence that these 
pharmacokinetic alterations were not associated with clini-
cally signiﬁ  cant abnormalities in laboratory parameters or 
serious adverse events (Fuhr and Jetter 2002). These ﬁ  ndings 
are in contrast to those for H2-receptor antagonists, wherein 
dosage adjustements are indicated if patients have moderate 
to severe renal function impairment (Feldman and Burton 
1990) but not in contrast with those for other PPIs.
Clinical efﬁ  cacy proﬁ  le in GERD
GERD is a common disease affecting a large part of Western 
population and progressively increasing in Eastern societ-
ies. There is an ongoing debate as to whether the different 
manifestations of prolonged reﬂ  ux of gastric content in the 
esophagus should be interpreted as a disease continuum 
(Pace and Bianchi Porro 2004) or as different and non-
communicating sub-groups (Fass and Ofman 2002). This 
debate is not only of theoretical relevance, because different 
natural courses of disease mean different expectations from 
the drugs we test against GERD, which in turn may affect 
the way we plan clinical studies. The ability to prevent the 
development of erosions in patients with symptoms, but 
without esophagitis (non-erosive reﬂ  ux disease, NERD), 
would be a strong endpoint for those considering GERD as 
a spectrum disease, while those who consider GERD an um-
brella covering different non-communicating diseases would 
possibly not even consider the possibility of progression to 
erosive disease. When possible, we will consider GERD as 
a spectrum disease, which has milder, non-erosive cases and 
longer lasting, worse, erosive or complicated cases. Data on 
atypical and extra-esophageal symptoms will be included as 
well. An extensive review (Carswell and Goa 2001) covered 
these topics in 2001 and we will focus only on papers pub-
lished after that date. 
GERD is associated with several symptoms, such as 
heartburn, belching, and regurgitation, which arise from 
esophageal exposure to gastric acid. Symptoms may occur 
with or without the presence of endoscopically observed 
esophageal mucosal damage and inﬂ  ammation. NERD pa-Therapeutics and Clinical Risk Management 2007:3(3) 368
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tients represent the majority of those who present with GERD 
symptoms. Although acid suppression therapy is a logical 
approach to relieve GERD symptoms, it has been thought to 
be less successful in patients with endoscopically negative 
or symptomatic GERD, than in those with erosive GERD. 
Some suggested (Gardner et al 2003) that this might be due 
to a decreased response to antisecretory agents in the post-
prandial period shown by NERD subjects. 
Non-erosive GERD
Miner et al (2002) report the results of a placebo-controlled, 
double blind study conducted on 203 patients with NERD and 
moderately severe GERD symptoms. After a 2-week, single-
blind, placebo run-in phase, patients were randomized to 
receive 10 mg or 20 mg of rabeprazole or placebo once daily 
for 4 weeks. Both doses of rabeprazole rapidly and effectively 
relieved heartburn, with signiﬁ  cant improvements on day 
1 of dosing, and an improvement of other GERD-related 
symptoms, including regurgitation, belching, bloating, early 
satiety, and nausea. Both doses were well tolerated without 
signiﬁ  cant difference among the two, but with a signiﬁ  cant 
superioriority over placebo with respect to time to the ﬁ  rst 
24-hour heartburn-free interval (2.5 and 4.5 days for 10 mg 
and 20 mg of rabeprazole, respectively, vs 21.5 days for the 
placebo), ﬁ  rst day-time or night-time heartburn-free interval 
(1.5–3 days for rabeprazole groups vs 12.5–15 days for the 
placebo), as well as to percentage of heartburn- and antacid-
free time (Miner et al 2002).
Another paper reported on the positive effects of ra-
beprazole therapy on GERD-related symptom distress, 
as measured with the GERD Symptom Assessment Scale 
(GSAS) (Damiano et al 2003). This scale was applied in 
two randomized, placebo-controlled trials of rabeprazole 
among patients with NERD. The age (mean ± SD) of the 
223 patients was 43.5 ± 11.9 years, and most were female 
(67%) and Caucasian (78%). Signiﬁ  cantly greater reductions 
in symptom distress were observed among patients receiv-
ing rabeprazole 20 mg daily for 4 weeks in comparison with 
those receiving placebo (–0.62 vs –0.36, p < 0.0001). The 
magnitude of this treatment-induced difference in GSAS was 
comparable with the differences in patient-perceived global 
rating (0.2 and 0.3 points, p < 0.0001).
A further study published by Kahrilas et al (2005) 
assessed the rapidity of symptom relief and 4-week efﬁ  cacy 
of rabeprazole 20 mg in patients with moderately severe 
NERD, collecting data from 2 similarly designed, double-
blind, placebo-controlled, multicenter, US trials. Two hun-
dred and sixty-one patients were randomized to 4 weeks of 
rabeprazole 20 mg once daily or placebo and were asked to 
score and daily record symptoms in diaries. Median time to 
ﬁ  rst 24-hour heartburn-free interval was signiﬁ  cantly shorter 
for the rabeprazole group than for the placebo group (3.5 
days vs. 19.5 days, p  0.0002). Complete heartburn relief 
at week 4 was 32% with rabeprazole and 3.8% with placebo 
(p  0.001). Regurgitation, belching, and early satiety were 
also signiﬁ  cantly improved by week 4 of rabeprazole treat-
ment, with a p  0.05. 
Fock et al (2005) studied the efficacy of rabeprazole vs 
esomeprazole in Asian patients with NERD, in a double-
blind study. One hundred and thirty-four patients with 
typical symptoms and normal endoscopy received either 
rabeprazole 10 mg or esomeprazole 20 mg once daily for 
4 weeks and kept daily diaries of symptoms, rating their 
severity. In this study rabeprazole 10 mg and esomepra-
zole 20 mg were comparable after 4 weeks of treatment 
with regard to the speed of action (time to achieve 24-hour 
symptom-free interval) for heartburn (8.5 vs 9 days) and 
regurgitation (6 vs 7.5 days) and patient’s global evalua-
tion at 4 weeks (96% on rabeprazole reported symptoms 
improvement vs 87.9% on esomeprazole, with p = NS). 
Satisfactory relief of day- and night-time symptoms was 
achieved in 98% of patients receiving rabeprazole and 
81.4% of patients receiving esomeprazole, although the 
difference was not statistically significant. 
NERD shows a deﬁ  nite tendency to relapse over time, 
similarly to the erosive form. Therefore the debate as to the 
optimal maintenance therapy for NERD is open. A logical 
consequence of the step-down treatment modality seems 
to be on-demand therapy (Pace et al 2002), which requires 
ideally a drug with a rapid onset of action. Unfortunately, 
there are very few studies comparing different PPIs used 
on-demand, with the only exception of a head-to head 
comparison of omeprazole with lansoprazole (Johnson et al 
2002). Rabeprazole might prove to have some characteristics 
of an ideal PPI in regards to on-demand therapy, since the 
intragastric pH during the ﬁ  rst 5–6 hours after a single dose 
of 20 mg rabeprazole is higher than after a single dose of 
20 mg omeprazole, in particular in H. pylori-negative men 
who are CYP2C19 homozygous or heterozygous extensive 
metabolizers (Inamori et al 2003).
In 2004 Ponce et al (2004) published a paper concerning 
on-demand therapy with rabeprazole in erosive and non-ero-
sive gastroesophageal reﬂ  ux disease. The effects of therapy 
were analysed in terms of efﬁ  cacy (absence of symptoms 
in a clinical questionnaire), health-related quality of life 
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patient satisfaction measured with a visual analogue scale. 
Fifty-ﬁ  ve patients (17 with NERD and 38 with low-grade 
esophagitis) were treated with rabeprazole 20 mg/day and 
those, healed clinically after 4 weeks (n = 51), took the 
medication in an on-demand way for 6 months. At the end of 
the study symptom control (heartburn < twice a week) had 
been achieved in over 85% of the patients. The mean (SD) 
amount of PPI used was 0.3 (0.19) tablet/day. The patient 
satisfaction score at the end of the acute phase was 98 
(range, 0–100) and remained high (90; range, 10–100) and 
stable during on-demand therapy. Short-term treatment 
normalized the HRQoL scores, which were subsequently 
maintained during on-demand therapy. 
A possible endpoint for on-demand therapy is to measure 
the time to unwillingness to continue treatment, although the 
validity of such a parameter has been questioned (Bytzer et al 
2004). During 2004 were published the results of a multicenter, 
randomized, double-blind, placebo-controlled, withdrawal 
study comparing 6 months of on-demand treatment with 
rabeprazole 10 mg vs placebo. Adults with a history of reﬂ  ux 
symptoms, a negative endoscopy and 3 days or more of moder-
ate to very severe heartburn in the 7 days before enrollment 
(n = 535) entered 4 weeks of open-label, acute treatment with 
rabeprazole 10 mg once daily. Eighty-three per cent of patients 
reported complete symptom relief and then entered the 6 
months on-demand phase. During on-demand treatment, rates 
of discontinuation because of inadequate heartburn control 
were 20% for placebo vs 6% for rabeprazole (p < 0.00001). 
Not surprisingly antacid use was two-fold higher in the placebo 
group than in the rabeprazole group (p = 0.0009).
Bour et al (2005) published a comparison of on-demand 
vs continuous long-term treatment of GERD and NERD with 
rabeprazole in patients with frequent symptomatic relapses. It 
was an open-label study, enrolling patients with mild erosive 
(Savary-Miller classiﬁ  cation grades 1 or 2) and non-erosive 
reﬂ  ux disease and frequent symptomatic relapses of at least 
moderate intensity in the previous year. After a 4-week selec-
tion phase with rabeprazole 10 mg once daily, patients report-
ing symptom relief were randomized to either rabeprazole 10 
mg continuous treatment or on-demand treatment for 6 months. 
One hundred and seventy-six patients were enrolled in the 
selection phase (men, 53%; mean age, 49 years; non-erosive 
reﬂ  ux disease, 36.4%; grade 1 esophagitis, 53.4%; grade 2 
esophagitis, 10.2%) and rabeprazole relieved symptoms in 
88.6%. Of this group, 152 were randomized to the comparative 
phase (continuous treatment, n = 81; on-demand treatment, 
n = 71). After 6 months symptom relief (2 points reduction 
on the symptoms rating scale) was slightly higher, 86.4% vs 
74.6%, for patients in the continuous treatment group com-
pared with those in the on-demand treatment group, but the 
difference was not statistically signiﬁ  cant (p = 0.065), as for 
the overall quality of life score. As expected, daily consump-
tion of rabeprazole was signiﬁ  cantly lower in the on-demand 
treatment group than in the continuous treatment one (0.31 
tablets vs 0.96 tablets; p < 0.0001). 
Comparability problems of these studies on on-demand 
treatment are due to a variable mix of GERD and NERD 
patients, to the deﬁ  nition of on-demand treatment and to 
different length of run-in periods.
Erosive reﬂ  ux disease (ERD) 
In patients with erosive GERD, primary endpoints are the rate 
of endoscopically conﬁ  rmed healing of ulcers and erosions 
and the decrease of frequency and severity of heartburn and 
associated GI symptoms. In the various studies reviewed, 
patients had endoscopically conﬁ  rmed esophagitis and all 
were adults. Standard exclusion criteria included recent 
treatment with therapeutic doses of a proton pump inhibitor 
or histamine H2-receptor antagonist, concurrent systemic dis-
orders and medical conditions that would prevent endoscopy. 
There was no common attitude towards H. pylori testing and 
attempt at eradication. 
Healing of esophagitis and symptom 
relief in ERD patients
Previously available literature (Dekkers et al 1999) indicated 
that rabeprazole 20 mg uid or 10 mg bid produced similar 
healing rates at 8 weeks, about 90%. Four-week healing rates 
paralleled these ﬁ  ndings, and most data suggested that the 
majority of patients responding to treatment did so already af-
ter 4 weeks. Rabeprazole and omeprazole were of similar efﬁ  -
cacy in relieving symptom frequency and severity at all time-
points, and their effect on overall well-being, as measured 
by the General Well-Being Schedule, appeared to be similar 
(Dekkers et al 1999; Caos et al 2000). In order to assess the 
relief from heartburn and from other symptoms of GERD 
after 3 days of treatment with standard-dose rabeprazole 
or high-dose omeprazole, healing rates and quantiﬁ  cation 
of antacid use, Holtmann et al (2002) studied 230 patients 
with endoscopically conﬁ  rmed erosive esophagitis that were 
randomized to receive 4 weeks of double-blind treatment with 
rabeprazole (20 mg) or omeprazole (40 mg). Patients who 
were not healed after 4 weeks received a further 4 weeks of 
treatment. There were no signiﬁ  cant differences between 
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relief from heartburn on day 4 (84% for rabeprazole; 95% 
conﬁ  dence interval (CI), 76%–90%; 83% for omeprazole; 
95% CI, 75%–89%) and from other gastro-esophageal reﬂ  ux 
disease symptoms or in healing rates. During the ﬁ  rst 3 days 
patients in the omeprazole group reported more frequently 
severe symptoms (day-time heartburn: 4.7% for rabeprazole 
vs 10.3% for omeprazole, p = 0.005; night-time heartburn: 
4.7% for rabeprazole vs 9.8% for omeprazole, p = 0.01; 
statistical comparisons deﬁ  ned post hoc). 
Robinson et al (2002) studied the onset of symptom 
relief with rabeprazole in a community-based, open-label 
assessment of patients with erosive esophagitis, enrolling 
2579 patients to receive rabeprazole (20 mg uid for 8 weeks). 
Symptoms were rated daily by patients through an interactive 
voice response system. On day 1, rabeprazole signiﬁ  cantly 
decreased day-time and night-time heartburn severity, re-
gurgitation, and belching. Complete relief of day-time and 
night-time heartburn were achieved in 64.0% and 69.2% of 
symptomatic patients, respectively, on day 1, and in 81.1% 
and 85.7% of patients, respectively, on day 7. Patients with 
moderate or severe heartburn symptoms at baseline achieved 
an even greater degree of satisfactory symptom relief (none 
or mild) from day 1 onwards. The median time to satisfac-
tory heartburn relief was 2 days. Subgroup analyses showed 
no consistent differences in efﬁ  cacy compared to the overall 
population treated. Health-related quality of life in patients 
was signiﬁ  cantly lower than that of the US general popula-
tion and improved signiﬁ  cantly after 8 weeks of rabeprazole 
therapy. Rabeprazole was well tolerated, with headache as 
the most common adverse event, reported by less than 2% 
of the study population. 
In order to identify any difference in the speed of reﬂ  ux 
esophagitis symptoms relief with omeprazole, lansoprazole, 
and rabeprazole, 85 patients with erosive reﬂ  ux esophagitis 
were randomized to receive omeprazole 20 mg uid, lansopra-
zole 30 mg uid, or rabeprazole 20 mg uid for 8 weeks (Adachi 
et al 2003), and daily symptoms were assessed in the ﬁ  rst 7 
days of administration. The mean heartburn score decreased 
more rapidly in patients receiving rabeprazole than the other 
PPIs. Patients receiving rabeprazole reached also earlier 
complete heartburn remission (rabeprazole vs omeprazole: 
p = 0.035, rabeprazole vs lansoprazole: p = 0.038 by log-
rank test). No differences were seen in the rate of endoscopic 
healing of reﬂ  ux esophagitis at 8 weeks between the three 
treatment regimens. 
Our group presented in 2005 (Pace et al 2005) the results 
of a study conducted in 560 Italian patients with Savary-
Miller grade I-III reﬂ  ux oesophagitis who were randomized 
in a double-blind, double-dummy fashion to rabeprazole or 
omeprazole 20 mg once daily for 4–8 weeks. At 4 to 8 weeks 
of treatment, healing rate was 97.9% in the rabeprazole group 
and 97.5% in the omeprazole one (p < 0.0001 at Blackwelder 
test), but time to the ﬁ  rst day with satisfactory heartburn relief 
was shorter with rabeprazole than with omeprazole (2.8 ± 0.2 
vs 4.7 ± 0.5 days, respecitively, p = 0.0045 at log-rank test). 
The Blackwelder test is a test to prove statistically equiva-
lence (ie, non-superiority) among two treatments. 
In a 8-week, prospective, multicenter, postauthorization 
surveillance study conducted in Greek clinical practices, and 
published by Archimandritis et al (2005), 273 patients with 
ERD were treated with rabeprazole 20 mg once daily for 4 
to 8 weeks. GERD symptom severity on day 1, 2, 3, and 7 
was measured using a 5-point scale and esophageal healing 
was evaluated performing endoscopy at baseline and after 
4 and 8 weeks of treatment. Already on day 1 of treatment, 
rabeprazole obtained a statistically signiﬁ  cant (p = 0.0001) 
improvement in heartburn, regurgitation, epigastric pain, and 
dysphagia across all grades of oesophagitis. Erosions healing 
rate was 77% at week 4 and 90% at week 8.
Relapse prevention 
Studies included in this section were randomized and 
double-blind, and required patients to have had a previous 
diagnosis of erosive GERD healed within 90 days of enrol-
ment, as demonstrated by endoscopy. At baseline endoscopy 
requirements included the absence of active erosions or 
ulcerations. The primary efﬁ  cacy endpoint in studies was 
the continued absence of esophageal erosions or ulcerations 
at follow-up endoscopic examinations. 
An early study compared rabeprazole with placebo 
(Birbara et al 2000), while a later one compared the daily 
dose of rabeprazole 20 mg with 10 mg (Caos et al 2000), 
and another one compared rabeprazole at the doses of 10 
and 20 mg daily with omeprazole (Thjodleifsson et al 2000). 
Relapse rates after 1 year of treatment were similar (about 
5%) with rabeprazole 10 or 20 mg/day and omeprazole 20 
mg/day in one study (Thjodleifsson et al 2000), while sig-
niﬁ  cantly different between rabeprazole 10 and 20 mg/day 
(10% vs 27%; p < 0.04) in the other (Caos et al 2000). No 
signiﬁ  cant differences between regimens were observed in 
secondary efﬁ  cacy variables such as frequency and sever-
ity of heartburn, overall well-being, time lost from usual 
activities of daily living, or antacid use. These studies 
reported also Kaplan-Meier probabilities for remaining 
free of severe day-time and night-time heartburn. Patients 
receiving rabeprazole were signiﬁ  cantly more likely to Therapeutics and Clinical Risk Management 2007:3(3) 371
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remain free of severe heartburn after one year of treatment 
than those receiving placebo in one trial (p < 0.0001) 
(Caos et al 2000) and there were no signiﬁ  cant differences 
between omeprazole and rabeprazole reported in the other 
(Thjodleifsson et al 2000).
A previous meta-analysis of comparative studies between 
PPIs (Dean et al 2001) included data from 1 unpublished 
study and 9 published studies, and indicated rabeprazole 
as more effective than other two proton pump inhibitors 
in preventing symptom recurrence in patients with GERD. 
The predicted recurrence rate for rabeprazole 20 mg/day 
was 0.14 (95% CI, 0.05–0.23) vs 0.32 (95% CI, 0.17–0.48) 
for lansoprazole 30 mg/day and 0.19 (95% CI, 0.07–0.32) 
for omeprazole 20 mg/day. Rabeprazole prevented 86% of 
symptom recurrences compared with 81% for omeprazole 
and 68% for lansoprazole. The authors of the study noted 
that these data were derived from only a small number of 
randomized trials and thus might overestimate the true level 
of efﬁ  cacy of each drug. 
The data concerning on-demand maintenance therapy 
have already been noted above (section on NERD). 
In our study (Pace et al 2005) 560 patients with Savary-
Miller grade I-III reﬂ  ux oesophagitis were endoscopically 
healed and symptomatically relieved with PPI treatment 
and then openly maintained with rabeprazole 10 mg uid, (or 
bid in the event of clinical and/or endoscopic relapse), for a 
maximum of 48 weeks. During this maintenance phase, an 
endoscopic and/or clinical relapse was observed in 15.2% 
of patients.
Considering that few trials of proton pump inhibitors in 
maintaining healing of erosive or ulcerative GERD are con-
ducted for longer than 1 year, Thjodleifsson and colleagues in 
2003 (Thjodleifsson et al 2003) published the comparison of 
the efﬁ  cacy and safety of 2 doses of rabeprazole with 20 mg 
omeprazole in the maintenance treatment of erosive GERD 
over 5 years. Two hundred and forty-three patients who had 
previously responded to acute treatment for erosive GERD 
were prospectively randomized to receive 5 years of treat-
ment with rabeprazole (10 or 20 mg daily) or omeprazole 
(20 mg daily). The primary outcome measure was endoscopi-
cally conﬁ  rmed relapse of erosive GERD. One hundred and 
twenty-three patients (51%) completed all 5 years of the 
study, with similar completion rates in the three groups. 
Relapses occurred in 9 of 78 (11.5%), 8 of 82 (9.8%), and 
11 of 83 (13.3%) patients in the rabeprazole 20 mg, rabe-
prazole 10 mg and omeprazole 20 mg groups, respectively. 
Gastric biopsy showed no evidence of any harmful effects. 
All treatments were well tolerated. 
In 2005 Caos et al (2005) presented the results of a 5-year 
maintenance study in 497 patients previously diagnosed with 
erosive/ulcerative GERD and healed in an acute efﬁ  cacy trial, 
receiving once-daily doses of 10 or 20 mg rabeprazole or 
placebo. After 5 years, relapse rates in the placebo group were 
signiﬁ  cantly higher than in both rabeprazole groups (placebo 
63%, rabeprazole 20 mg 11%, rabeprazole 10 mg 23%, 
p < 0.001). The relapses in the two dosages groups were also 
signiﬁ  cantly different (p = 0.005). Both rabeprazole doses 
were signiﬁ  cantly superior to placebo in preventing relapse 
of heartburn frequency and improving patient quality of life. 
Analyses of adverse events, biopsy ﬁ  ndings and laboratory 
values showed no evidence of clinically signiﬁ  cant effects. 
Barrett’s esophagus (BE) 
Some studies assessed the question concerning the effects 
of PPI therapy on esophageal acid and bile exposition, in 
an attempt to evaluate the proper PPI therapy in this subset 
of patients.
To evaluate oesophageal acid exposure in a large BE 
population and determine clinical factors predicting nor-
malization of intra-oesophageal pH, 46 BE patients on rabe-
prazole twice a day therapy were studied using 24-hour pH 
monitoring (Wani et al 2005). Median total percentage time 
pH < 4 was 1.05% (range: 0%–29.9%) in the entire group 
and respective values for upright and supine percentage time 
pH < 4 were 1.15% and 0%. However, 34 of the BE patients 
(73.9%) had a normal pH study (median total percentage time 
pH < 4: 0.2%) and 12 patients (26.1%) had an abnormal result 
(median total percentage time pH < 4: 9.3%). There were no 
signiﬁ  cant differences between patients with a normal and 
abnormal 24-hour pH result with respect to age, BE length, 
hiatal hernia size and presence of H. pylori infection. 
Another prospective study (Gerson et al 2005) was 
conducted in BE patients already on PPI therapy in order to 
determine whether a shift to rabeprazole at a dose titrated 
for symptom relief could alter intra-oesophageal and intra-
gastric acid suppression. Seventeen H. pylori-negative BE 
patients were studied with 24-hour pH monitoring for a ﬁ  rst 
time during omeprazole or lansoprazole therapy, and for a 
second time on rabeprazole. Ten out of 17 (59%) patients 
had abnormal baseline intra-esophageal pH proﬁ  les under 
omeprazole or lansoprazole and 8 out of 10 were still abnor-
mal on rabeprazole. Intra-gastric pH was out of control in all 
the BE patients, who demonstrated the phenomenon of noc-
turnal acid breakthrough, and a mean time with intra-gastric 
pH below 4.0 of 46% on omeprazole, 71% on lansoprazole, 
and 51% on rabeprazole (p = 0.25). Therapeutics and Clinical Risk Management 2007:3(3) 372
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Elimination of acid reﬂ  ux, conﬁ  rmed by means of 24-hour 
esophageal pH-monitoring, was achieved using 40 mg rabe-
prazole 3 times per day in a recent study (Johnston et al 2005) 
planned to evaluate the safety and the efﬁ  cacy of a new cryo-
genic device to perform endoscopic Barrett’s mucosa ablation. 
In that study 11 subjects were treated with disappearance of 
BE in 78% patients and no subsquamous specialized intesti-
nal metaplasia at the 6-month follow-up. These preliminary 
results show that cryoablation of BE under direct endoscopic 
visualization is safe and easy to perform and suggest that it 
could be a treatment modality worth further exploration in the 
ablation of GI mucosal lesions such as BE.
Atypical (or extra-esophageal) 
symptoms
Although considered a relevant problem in gastroenterology, the 
therapy of atypical or extraesophageal manifestations of GERD 
has been subjected to considerably less studies than the typical 
manifestations. In particular, direct comparison of PPIs are gen-
erally lacking; as an example, in the recent Cochrane review on 
the therapy of GERD-induced asthma with antisecretory agents 
(Gibson et al 2003), all PPI studies were placebo-controlled. 
The studies with rabeprazole conducted on atypical GERD 
manifestations include the treatment of dysphagia, chest pain, 
laryngitis and GERD-induced respiratory and sleep disorders; 
most of them are open-label and uncontrolled studies.
To determine whether dysphagia associated with GERD 
could be effectively treated with rabeprazole, 68 outpatients 
with gastroesophageal reﬂ  ux-associated dysphagia (Oda et al 
2005) were studied with upper endoscopy (52 out of 68 had 
esophagitis) and then treated with rabeprazole 20 mg daily for 
8 weeks. A further 6 months of treatment at 10 mg/day were 
warranted for those 16 subjects whose dysphagia improved. 
At the sixth month dysphagia was completely resolved in 
40 subjects, improved partially in 20, and was unchanged 
in 8 subjects. Comparison between complete therapeutic 
successes and partial or total failures demonstrated that only 
improvement in heartburn symptoms seemed to correlate 
with efﬁ  cacy of rabeprazole on dysphagia. 
The use of rabeprazole in the empirical diagnosis of 
GERD-related chest-pain (the so called PPI test) has been 
assessed in a recent (Dickman et al 2005) double-blind, 
randomized, placebo-controlled, crossover trial, that dem-
onstrated a sensitivity of 75% and a speciﬁ  city of 90% for 
rabeprazole 20 mg bid, administered for 7 days in a thera-
peutic trial. 
Treatment with rabeprazole 20 mg/day has shown to 
improve by more than 20% the peak expiratory ﬂ  ow (PEF) in 
40% of asthma patients also suffering from GERD (Tsugeno 
et al 2003). The probability of getting a clinically relevant 
improvement in PEF with rabeprazole therapy is related to 
the intensity of GERD symptoms and the lack of steroid-
dependency of asthma. The ﬁ  ndings of another study (Oribe 
et al 2005) show that rabeprazole, but not histamine H2-
blockers, can directly decrease cough reﬂ  ex hypersensitivity 
induced with an antigenic aerosol in guinea-pigs and elicited 
after 24 hours with capsaicin. Noteworthy, rabeprazole does 
not act reversing the pH drop in the bronchial washing ﬂ  uid 
observed in antigen-challenged animals. 
GERD is associated also with lower sleep quality. One 
week of therapy with 20 mg rabeprazole bid in GERD 
patients ameliorates subjective measures of sleep quality 
and overall acid reﬂ  ux, but not objective sleep measures and 
night-time acid contact, as shown by polysomnography and 
24-hour pH monitoring (Orr et al 2005).
Another well-known extraesophageal manifestation 
of GERD is chronic laryngitis. An open label study 
(Klopocka et al 2004) tried to estimate the efficacy of 2 
months of 20 mg rabeprazole bid treatment in patients 
with long history of chronic idiopathic laryngitis, but 
without typical GERD symptoms. There was remarkably 
good therapeutic outcome, with hoarseness and pharyn-
geal pain resolved, respectively, in 68.7% and 78.5% 
of patients and laryngeal signs in 50%–80%. However, 
weak tension of vocal cords, which was often seen in 
these patients before the trial, persisted. A double-blind, 
randomized trial (Steward et al 2004) comparing 2-month 
lifestyle modification therapy plus rabeprazole 20 mg bid 
or placebo in chronic GERD-related laryngo-pharyngitis 
deserves careful examination. In this study good compli-
ance with lifestyle modification significantly improved 
laryngo-pharyngitis symptoms, but adding rabeprazole 
did not significantly improve typical reflux symptoms, 
health status, or laryngeal appearance. The only two 
factors predicting good outcome on laryngeal symptoms 
seemed to be a good compliance to lifestyle modifica-
tion and a positive effect on typical symptoms. Possible 
studies with 24-hour esophageal impedance monitoring 
in ear, nose, and throat of patients might allow stratifying 
these patients and defining standard length of treatment 
and more objective outcome measures.
Another study, again open-label and uncontrolled (Swiat-
kowski et al 2004), was conducted to estimate the effects of 
gastric acid output suppression with rabeprazole on course of 
angina pectoris and the results of the treadmill stress test in 
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rabeprazole 20 mg bid signiﬁ  cantly decreases the frequency 
of angina-like chest pain and improves the results of the 
treadmill stress test, which implies that at least some of their 
symptoms are related to GERD.
Helicobacter pylori eradication 
and peptic ulcer healing
Considering the fact that many publications have ap-
peared on the subject, our aim is to highlight only the most 
significant data published in recent years. A systematic 
review by Gisbert et al (2003) evidenced that rabeprazole 
achieves similar H. pylori eradication rates compared 
with omeprazole and lansoprazole when co-adminis-
trated with low or high doses of antibiotics (amoxicillin 
and clarithromycin). In addition to this, as shown by the 
above-reported review, low doses of rabeprazole (10 
mg/bid) may be sufficient to eradicate H. pylori when 
administered with two antibiotics.
These results are consistent with data from Di Mario 
et al (2003). Ninety-four H. pylori-positive patients with 
dyspeptic symptoms were equally randomized to receive 
a 1-week regimen based on rabeprazole 10 mg/bid or 20 
mg/bid plus clarithromycin 500 mg/bid and tinidazole 500 
mg/bid. An urea breath test, performed 2 months after the 
end of the therapy, evidenced a comparable eradication rate 
between the two groups: 89.3% for rabeprazole 10 mg and 
91.4% for rabeprazole 20 mg (p = ns).
Although a 7-day scheme is the optimal treatment to 
achieve good eradication rates, some authors have dem-
onstrated that rabeprazole is also effective with shorter 
regimens. In 128 dyspeptic patients rabeprazole 20 mg/bid, 
together with clarithromycin 250 mg/bid and metronidazole 
500 mg/bid, achieved 81% and 88% (respectively intention-
to-treat and per-protocol analysis) eradication rates with 
a 4-day regimen vs 78% and 85% after a 7-day treatment 
(Gambaro et al 2003).
Yang and Giannini showed, separately, that the 
rabeprazole-based triple therapy could be shortened to 4 
days without reducing its efﬁ  cacy. In the work of Yang et al 
(2003) the intention-to-treat and the per-protocol analysis 
demonstrated that rabeprazole 20 mg/bid + clarithromy-
cin 500 mg/bid + amoxicillin 1000 mg/bid eradicated the 
H. pylori infection in 87% and 91% of patients after 4 days 
of therapy in comparison with 83% and 95% for rabeprazole 
20 mg/bid and with 88% and 100% for omeprazole 20 mg/bid 
after a 7-day regimen.
Giannini et al (2006) investigated 85 patients, who failed 
at least one H. pylori eradication before being randomized to 
receive rabeprazole 20 mg/bid + levoﬂ  oxacin 500 mg/bid + 
tinidazole 500 mg/bid either for 4 or 7 days. The cure rate 
was, respectively, 83% in both intention-to-treat and per-
protocol analysis for the 4-day scheme and 84% and 86% 
for the 7-day one.
Wang et al (2005) showed that a very short-term eradica-
tion regimen could be an optimal strategy; they prospectively 
evaluated 115 patients with H. pylori-infected active peptic 
ulcer, treating them with an even shorter triple therapy. 
Patients received in an open and random design the fol-
lowing scheme: rabeprazole 20 mg + clarithromycin 500 
mg + amoxicillin 1000 mg all twice daily for 3 or 7 days; 
afterwards, all patients took rabeprazole 20 mg/uid until the 
eighth week. Three months after the therapy, the infection 
was cured in 84.6% vs 87.5% of patients, respectively (per-
protocol analysis, p = 0.68). One year after the therapy, 75 
patients repeated the urea breath test, conﬁ  rming an eradica-
tion rate of 78.4% vs 81.6% for the 3- and 7-day regimen 
(per-protocol analysis, p = 0.73).
In the United States previous guidelines recommended 
a 10- to 14-day treatment due to scarcely reproducible data 
from 7-day American trials. Vakil et al (2004) showed that 
a 1-week therapy with rabeprazole 20 mg/bid, together with 
clarithromycin 500 mg/bid and amoxicillin 1000 mg/bid, is 
as effective as a 10-day rabeprazole- or omeprazole-based 
regimen in eradicating the infection. This was a double-blind, 
randomized, parallel-group trial, investigating 803 patients 
with or without peptic ulcer. A urea breath test, performed 
6 weeks after the end of the therapy, assessed a cure rate of 
77% for the 7-day rabeprazole-based regimen compared with 
78% and 73% for the 10-day rabeprazole- or omeprazole-
based therapy.
A recent publication has evidenced the reproducible 
eradication rates of rabeprazole between subjects with dif-
ferent hepatic metabolism due to CYP2C19 polymorphism. 
One hundred and eighty-seven H. pylori-infected peptic 
ulcer patients were randomly treated with either rabeprazole 
10 mg/bid or lansoprazole 30 mg/bid plus amoxicillin 750 
mg/bid and clarithromycin 400 mg/bid for 1 week. The 
eradication rates in the RAC and LAC groups were 75%, 
and 69% respectively, in the intention-to-treat analysis, and 
80% and 75% respectively, on a per-protocol basis. When 
stratiﬁ  ed for CYP2C19 polymorphism, the cure rate in RAC 
extensive metabolizers was less affected by variability than 
that in LAC ones: 86%, 91%, and 86% respectively for 
homozygous extensive metabolizers, heterozygous extensive 
metabolizers and poor metabolizers in the RAC group, com-
pared with 74%, 83%, and 100% respectively for the same Therapeutics and Clinical Risk Management 2007:3(3) 374
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subgroups of metabolizers in the LAC group (the data were 
obtained in subjects with strains sensitive to clarithromycin) 
(Kawabata et al 2003).
In 2005 Gisbert and Pajares (2005) questioned if a 1-week 
PPI-based triple therapy is enough to heal peptic ulcer. They 
performed a systematic review of 24 studies (2342 patients) 
where peptic ulcer healing was assessed in 1289 patients after 
just a 7-day PPI-based triple therapy. In addition to this they 
evaluated trials through a meta-analysis, comparing the efﬁ  cacy 
on ulcer healing of this regimen vs the same scheme, but pro-
longing the PPI for a further 2–4 weeks. The authors concluded 
that a 7-day triple therapy is sufﬁ  cient to promote ulcer healing; 
in fact, the healing rate was 86% and 95%, respectively, in all 
patients (both with H. pylori eradication success and failure) 
and in patients successfully eradicated. Two or more weeks of 
prolonged PPI therapy did not ameliorate these ﬁ  gures (91% 
with only 1 week of triple therapy vs 92% with prolonged PPI 
treatment, odds ratio = 1.11, 95% CI, 0.71–1.74).
Rabeprazole was demonstrated to be as effective as 
omeprazole in healing duodenal ulcer after a 1-week triple 
therapy. One hundred and seventy-three patients received in 
a random way rabeprazole 20 mg for 3 days or rabeprazole 
10 mg for 7 days plus amoxicillin 1000 mg and clarithromy-
cin 500 mg (RAC therapy) or omeprazole 20 mg for 7 days 
plus amoxicillin 1000 mg and clarithromycin 500 mg (OAC 
therapy) (all drugs twice daily). Six weeks after the end of 
treatment the endoscopy evidenced duodenal ulcer healing in 
73% of 3-day RAC group and 89% of both 7-day RAC and 
OAC groups (intention-to-treat analysis). In the per-protocol 
population the rates were comparable, respectively 73%, 
100%, and 89%. The H. pylori infection was eradicated in 
72%, 88%, and 82% of intention-to-treat group (similar data 
in per-protocol patients) (Wong et al 2001).
Even a 10-day PPI treatment once daily, coadministered 
with amoxicillin 1000 mg/bid and clarithromycin 500 mg/bid 
(the antibiotics for only 5 days) has been proven to heal duo-
denal ulcers. One hundred and twenty-seven patients were 
randomized into 3 groups: rabeprazole 20 mg, rabeprazole 
40 mg and omeprazole 40 mg. The intention-to-treat analysis 
evidenced comparable (differences not statistically signiﬁ  -
cant) cure rates between the groups: 85.7% for rabeprazole 
20 mg, 90% for rabeprazole 40 mg and 93.3% for omeprazole 
40 mg (Catalano et al 2002).
Ando et al (2005) recently demonstrated that healing 
efﬁ  cacy of rabeprazole is less inﬂ  uenced by CYP2C19 
genetic polymorphism than that of omeprazole and, hence, 
this attitude can result in an earlier repair of gastric mucosal 
damage. Eighty patients with active gastric ulcer received ra-
beprazole 10 mg or omeprazole 20 mg once daily for 8 weeks. 
The improvement of gastric ulcer size and ulcer healing rates 
were stratiﬁ  ed per CYP2C19 subgroups metabolizers after 
2 and 8 weeks of treatment. The mean 2-week posttreat-
ment ulcer size differed signiﬁ  cantly between metabolizers 
in omeprazole group (35.8 ± 45.2 mm2 vs 14.6 ± 16.2 mm2 
vs 33.9 ± 53.0 mm2 respectively for homozygous extensive 
metabolizers, heterozygous extensive metabolizers and poor 
metabolizers), but not in rabeprazole one (8.4 ± 8.4 mm2 vs 
8.9 ± 9.5 mm2 vs 18.2 ± 14.7 mm2), leading to a statistical 
difference between rabeprazole and omeprazole homozygous 
extensive metabolizers (p = 0.0057). At 8 weeks both PPIs 
showed similar high healing ﬁ  gures. Even the percentage 
healing ratios of ulcer areas were more reproducible in 
rabeprazole group at 2 weeks (80.7 ± 17.4% vs 89.3 ± 12.5% 
vs 84.3 ± 13.2%, respectively, for homozygous extensive 
metabolizers, heterozygous extensive metabolizers, and 
poor metabolizers), than in omeprazole one (63.4 ± 24.6% 
vs 85.2 ± 12.2% vs 84.0 ± 16.4%, p = 0.0347 rabeprazole 
vs omeprazole in homozygous extensive metabolizers), 
resulting in an overall signiﬁ  cant difference (85.9 ± 14.4% 
vs 76.5 ± 21.0%, p = 0.0210 rabeprazole vs omeprazole total 
healing rate).
Finally, low-dose rabeprazole could achieve the same 
ulcer healing rates as full-dose omeprazole in 112 patients 
with at least one active gastric antral or duodenal ulcer 
(diameter 5 mm to 30 mm) at baseline visit. Patients 
received rabeprazole 10 mg or omeprazole 20 mg once daily 
for 6 weeks and were evaluated endoscopically and clini-
cally (symptom severity) at 1 and 6 weeks of treatment. The 
remaining ratios of peptic ulcers were equivalent in both 
groups after 1 week of therapy (45.5 ± 33.0% vs 50.3 ± 
35.2%, p = 0.475 rabeprazole vs omeprazole) and at 6 weeks 
(80.6% vs 87.0%, p = 0.423 rabeprazole vs omeprazole). 
Day pain and night pain severity consistently decreased in 
both groups at 6 weeks (patients with day pain and night 
pain resolution were respectively 63.6% and 72.4% in 
rabeprazole group vs 64.3% and 73.1% in omeprazole one, 
p = ns) (Ji et al 2006).
Pharmacoeconomics and quality 
of life
Since GERD is a chronic, relapsing condition with probably 
the majority of patients requiring long-term maintenance 
therapy, prescription rates and attendant costs of PPIs con-
tinue to rise. The initial choice of treatment has, therefore, 
long-term cost implications. Therapeutics and Clinical Risk Management 2007:3(3) 375
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A model including medical costs for hospitalizations, 
procedures, and ofﬁ  ce visits was developed (Ofman et al 
2000) to compare the cost-effectiveness of rabeprazole and 
ranitidine in acute and maintenance therapy for erosive 
esophagitis using symptom response, rather than endoscopic 
healing, as the clinical outcome. The per-patient cost of 
rabeprazole therapy resulted higher than that of ranitidine 
therapy (US$2020 vs US$1917), but rabeprazole was more 
effective in preventing symptomatic recurrences (74% vs 
41%). Rabeprazole had also a lower average cost-effective-
ness ratio than ranitidine (US$2748 vs US$4719 per symp-
tomatic recurrence prevented). Therefore management of 
esophagitis with rabeprazole is more effective and may be 
more cost effective, than with generic ranitidine. 
PPI prescriptions might be appropriate or not. In an Irish 
general hospital (Mat Saad et al 2005), where the 30.6% 
of inpatients were on PPI therapy, up to one-third of cases 
had an unapproved or unknown indication, and even if the 
70.8% of PPI therapies had been initiated in hospital, only 
one-third of the patients on PPI therapy had undergone 
endoscopy. Rabeprazole, the least expensive PPI, was the 
least prescribed. Of note, the substitution of the PPI with the 
greatest individual cost with any of the alternative agents, par-
ticularly the generics omeprazole preparations, rabeprazole, 
and pantoprazole, in accordance with therapeutic indication, 
would be expected to produce important cost savings. Deci-
sion analysis was used (Ofman et al 2002) to calculate the 
clinical and economic outcomes of competing (traditional 
step-up plus endoscopy vs PPI test plus step-down therapy) 
management strategies. Based on the results of this analysis, 
PPI test followed by a “step-down” approach may result in 
improved symptom relief and quality of life over 1 year, and 
more appropriate utilization of invasive diagnostic testing at 
a small marginal increase in total costs. 
Savings might be further enhanced by increasing the 
step-down strategy from healing to maintenance doses of 
these drugs (McGowan et al 2005). 
In order to compare the costs and effectiveness of treat-
ment of not investigated GERD with other available PPIs, 
even in generic formulations, a treatment model was devel-
oped incorporating acute treatment, long-term continuous, or 
on-demand maintenance therapy and number of endoscopies 
to conﬁ  rm diagnosis (Remak et al 2005). Generic omeprazole 
and rabeprazole cost less and resulted in more symptom-free 
days and higher quality-adjusted life years (QALY) gains 
than the other PPIs. Moreover, rabeprazole had a favorable 
cost-effectiveness ratio of £3.42 per symptom-free day and 
£8308 per quality-adjusted life-year gained when compared 
with generic omeprazole, remaining cost-effective indepen-
dently of choice of continuous vs on-demand treatment.
In another model (Dubois et al 2005) developed for 
endoscopy-conﬁ  rmed NERD patients in the UK, on-demand 
use of rabeprazole incurred the lowest cost in comparison 
with the other PPIs, with base-case annual median cost and 
utility gained with on-demand rabeprazole therapy respec-
tively of €123 euro and 0.89. Differences in costs, but not in 
outcomes, were statistically signiﬁ  cant, and the results were 
robust to sensitivity analyses.
All PPIs that have holding time of intragastric pH >4 
for at least 11 hours in 24-hour period; a study has been 
conducted aiming at correlating cost of therapy with holding-
time characteristics of 4 PPIs (esomeprazole, lansoprazole, 
omeprazole, and rabeprazole) (Kivioja et al 2004). The cost-
minimization analysis produced 2 least expensive PPIs, one 
in the range of 11 hours or more of holding time and one 
in the range of 12 hours or more, which were respectively 
lansoprazole (average cost of €138.89 per patient) and rabe-
prazole (€193.81 per patient).
A large study conducted on 75,452 newly diagnosed 
GERD subjects (Hall et al 2002) revealed 67.9% of subjects 
treated with lansoprazole, 30.3% treated with omeprazole, 
and only 1.8% under rabeprazole treatment. In this cohort 
rabeprazole subjects had lower GERD-related costs, less 
escalation to higher drug dosages, and fewer tablets con-
sumed per day, compared with lansoprazole and omeprazole 
subjects. Compliance was not signiﬁ  cantly different between 
the drugs, and increased compliance did not decrease GERD-
related costs. 
In 2000 Farley et al (2000) compared rabeprazole and 
the histamine H2-receptor antagonist ranitidine in the treat-
ment of erosive gastroesophageal reﬂ  ux disease. Patients 
were randomized to rabeprazole 20 mg daily or to ranitidine 
150 mg 4 times daily, and evaluated for heartburn symptoms, 
overall sense of wellbeing, time lost from daily activities, 
antacid use, and adverse events. At weeks 4 and 8 there were 
signiﬁ  cant differences favoring rabeprazole with respect 
to resolution or improvement of heartburn symptoms and 
improvement in sense of wellbeing, which can be considered 
a non-speciﬁ  c form of quality of life measurement.
Johanson et al (2002) assessed the effect of rabeprazole 
20 mg once a day on quality of life of reﬂ  uxers participat-
ing in an open-label, 8-week, study, as measured with the 
SF-36 Health Survey. All SF-36 scales mean scores improved 
signiﬁ  cantly (p  0.007) from baseline to week 8. All the 
improvements were also clinically meaningful, except for 
physical functioning, general health and mental health. Therapeutics and Clinical Risk Management 2007:3(3) 376
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Rabeprazole treatment normalized baseline scores in role 
limitations due to physical problems, social functioning, role 
limitations due to emotional problems, and mental health that 
were signiﬁ  cantly poorer than those of the general population 
at the beginning of the study.
To determine the influence of H. pylori infection on 
effectiveness of rabeprazole in primary and secondary 
care, Wit et al (2004) tested for H. pylori 1787 patients 
from primary and secondary care centers with unin-
vestigated suspected GERD (based on symptoms only) 
and investigated GERD (endoscopically confirmed 
oesophagitis or endoscopy-negative reflux disease) and 
then treated them with rabeprazole 20 mg once daily for 
4–8 weeks in a non-randomized, multicenter, open-label 
study. Resolution of both heartburn and acid regurgitation 
was evaluated at 4 and 8 weeks, as well as quality of life 
as registred with the Psychological General Well-being 
Index. Mean duration of treatment was 36.3 days. At the 
re-evaluation visit 76.9% were heartburn-free, 77.7% 
regurgitation-free, and 71% had complete symptom reso-
lution. Overall Psychological General Well-being Index 
scores improved accordingly. Treatment was equally 
effective in patients with or without H. pylori infection, 
but more effective in patients with esophagitis when 
compared with non-erosive GERD. 
Possible new indications
A mechanism of tumor resistance to chemotherapy may be 
the alteration of the tumor microenvironment via changes in 
the pH gradient between the extracellular environment and 
the cell cytoplasm (De Milito and Fais 2005), impairing the 
uptake of weakly basic chemotherapeutic drugs, and reducing 
their effect. An option to revert multi-drug resistance could 
be to target the vacuolar H+-ATPases (V-H+-ATPases) that 
pump protons across the plasma membrane. Rabeprazole 
directly inhibits V-H+-ATPases and PPI pretreatment sen-
sitizes tumour cell lines to the effect of cisplatin, 5-ﬂ  uoro-
uracil and vinblastine. PPI pretreatment was associated with 
the inhibition of V-H+-ATPases activity and an increase of 
both extracellular pH and the pH of lysosomal organelles, 
consistent with a cytoplasmic retention of the cytotoxic drugs 
and targeting to the nucleus in the case of doxorubicin. An in 
vitro study (Itagaki et al 2004) revealed that extremely high 
concentrations of rabeprazole increase rhodamine 123 uptake 
via MDR1 between 68% and 185% in Caco-2, HeLa and 
Hvr100-6. At the levels observed in plasma (approximately 
1 µM), the drug interaction with MDR1 should be minimal 
in patients under rabeprazole treatment.
The substituted benzimidazoles omeprazole, lansopra-
zole, rabeprazole, and pantoprazole were also found to have 
in vitro activity against three different isolates of Plasmodium 
falciparum (Riel et al 2002), some of which are chloroquine 
and pyrimethamine resistant or multidrug resistant. Lanso-
prazole and rabeprazole were the most effective. Further 
studies are needed to ascertain if there is a clinical correlate 
of these in vitro properties.
Notes
Data selection 
Sources: Medical literature published in English up to spring 
2006 since January 2001 (included) concerning clinical 
studies, and since January 1999 concerning pharmacological 
studies, conducted with rabeprazole, identiﬁ  ed using Medline 
and EMBASE. 
Selection: studies in patients with acid-related disorders, 
primarily GERD and peptic ulcer, who received rabeprazole. 
Relevant pharmacodynamic and pharmacokinetic data are 
also included.
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